Labcorp Posts 9.5 Percent Gain in Q2

Laboratory Corporation of America (Labcorp) delivered strong Q2 2025 results, with GAAP revenue of $3.53 billion (up 9.5% year-over-year) and adjusted EPS of $4.35 (up 10.4%), both exceeding analyst expectations. This performance, fueled by robust demand across its Diagnostics and Biopharma segments and operational efficiencies, prompted management to raise its full-year 2025 guidance for revenue, adjusted EPS, and free cash flow, signaling continued confidence in its operational momentum and strategic initiatives, including new specialty tests and shareholder returns.

Analysis

Laboratory Corporation of America (LH) reported a robust second quarter for 2025, exceeding analyst expectations with GAAP revenue of $3.53 billion, a 9.5% year-over-year increase, and adjusted EPS of $4.35, up 10.4%. This performance was driven by broad-based strength, with the Diagnostics Laboratories segment growing revenue by 8.9% on the back of a 4.9% increase in requisition volume and contributions from recent acquisitions. The Biopharma Laboratory Services segment demonstrated even stronger momentum, with revenue climbing 11.0%, propelled by a significant 20.4% surge in Early Development services and supported by a healthy $8.71 billion backlog that provides solid future revenue visibility. Profitability also improved, with the adjusted operating margin expanding to 15.1% from 14.9% in the prior year, reflecting organic growth and operational efficiencies. This strong operational execution and positive outlook led management to raise its full-year 2025 guidance for revenue, adjusted EPS, and free cash flow, while continuing shareholder returns with a $200 million share repurchase during the quarter. While the ongoing integration of Invitae slightly weighed on Diagnostics margins, management expects it to become accretive to earnings by the end of 2025, signaling confidence in resolving this minor headwind.

Key Decisions for Investors

• Given the strong beat-and-raise quarter and upwardly revised full-year guidance, investors should view the results as a validation of the company's growth strategy and operational strength in both its Diagnostics and Biopharma segments.
• It is critical to monitor the progress of the Invitae integration and management's ability to achieve earnings accretion by year-end 2025, as this will be a key determinant of future margin expansion.
• Investors should track the conversion of the robust $8.71 billion Biopharma backlog as a leading indicator of sustained growth, while also remaining cognizant of external risks like reimbursement policy changes and inflation, which management has identified as manageable but persistent factors.